{"symbol":"BMY","fiscalQuarter":"Q3-2022","reportDate":"2022-10-25","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2022","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 0.3%","keyNumbers":[{"metric":"EPS","actual":"$1.99","expected":"N/A","surprise":"+8.80%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering innovative treatments to patients."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb reported better-than-expected earnings per share, which reflects positively on their operational efficiency. However, the stock fell slightly by 0.3%, indicating that investors may have been looking for more comprehensive guidance or revenue figures. The lack of revenue data and future guidance could lead to uncertainty among investors moving forward.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2022 earnings: EPS beat by 8.80%. Stock down 0.3%. Full breakdown."}}